Replimune Group (NASDAQ:REPL) Shares Climb 8.3% – Time to Buy?

Replimune Group, Inc. (NASDAQ:REPL) was up 8.3% during trading on Monday. The company traded as high as $19.09 and last traded at $19.0740. Approximately 4,814,670 shares traded hands during mid-day trading, an increase of 11% from the average session volume of 4,332,466 shares. The stock had previously closed at $17.61.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Wolfe Research upgraded Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price target on the stock in a report on Friday, August 7th. Leerink Partners lifted their price target on shares of Replimune Group from $19.00 to $31.00 and gave the stock an “outperform” rating in a report on Thursday, October 29th. Wall Street Zen raised Replimune Group from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Piper Sandler raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Replimune Group currently has an average rating of “Moderate Buy” and a consensus target price of $14.33.

Replimune Group Stock Up 0.2%

The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of -7.42 and a beta of 0.93. The company has a quick ratio of 6.90, a current ratio of 7.11 and a debt-to-equity ratio of 0.59. The company’s 50 day moving average price is $13.79 and its 200 day moving average price is $9.47.

Replimune Group (NASDAQ:REPL) last released its earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.24. As a group, research analysts forecast that Replimune Group, Inc. will post -2.40 earnings per share for the current fiscal year.

Insider Transactions at Replimune Group

In related news, CAO Andrew Schwendenman sold 7,632 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $98,987.04. Following the sale, the chief accounting officer owned 99,425 shares in the company, valued at $1,289,542.25. This represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $510,252.77. Following the completion of the transaction, the chief executive officer owned 708,151 shares in the company, valued at approximately $9,184,718.47. This trade represents a 5.26% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 100,624 shares of company stock valued at $1,446,864. 5.40% of the stock is owned by company insiders.

Institutional Trading of Replimune Group

Large investors have recently made changes to their positions in the business. Quantinno Capital Management LP increased its stake in shares of Replimune Group by 782.7% in the first quarter. Quantinno Capital Management LP now owns 108,477 shares of the company’s stock worth $830,000 after acquiring an additional 96,188 shares during the period. Montanova Capital LLC lifted its position in Replimune Group by 4.0% during the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock valued at $48,595,000 after purchasing an additional 168,000 shares during the period. Seven Fleet Capital Management LP acquired a new position in Replimune Group during the first quarter valued at $921,000. Squarepoint Ops LLC acquired a new position in Replimune Group during the second quarter valued at $1,454,000. Finally, Deutsche Bank AG purchased a new stake in Replimune Group in the second quarter valued at $857,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.